Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708569 | 0.89 | RXFP1 (0.39) | BRD4CREBBPBRD2ROCK2LMNA | |
| SCHEMBL6710099 | 0.89 | HIF1A (0.35) | BRD4CREBBPBRD2USP30LMNA | |
| SCHEMBL6710311 | 0.87 | FTO (0.41) | BRD4LCKFYNCREBBPUSP30 | |
| SCHEMBL6707644 | 0.85 | LMNA (0.38) | LCKROCK2USP30LMNA | |
| SCHEMBL6709982 | 0.84 | MAPT (0.38) | NR3C2LMNA | |
| SCHEMBL6834548 | 0.83 | BRD4 (0.41) | BRD4LCKFYNCREBBPBRD2 | |
| SCHEMBL6713616 | 0.82 | CCKAR (0.37) | LCKROCK2LMNA | |
| SCHEMBL6711975 | 0.81 | TRPA1 (0.46) | LCKROCK2LMNA | |
| SCHEMBL6710142 | 0.81 | ROCK2 (0.41) | ROCK2 | |
| SCHEMBL6708021 | 0.81 | MAPT (0.41) | LCKFYNROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | BRD4 1588/4885LCK 4247/4885FYN 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.